INDIVIOR PHARMACEUTICALS, INC.

Drug pipeline (8)

Asset	Stage	Revenue	Trials	Status
SUBLOCADE	approved	$253.0MQ2 2026	19	approved
PERSERIS KIT	approved	$5.0MQ2 2026	68	approved
BUPRENEX	approved	—	3	approved
OPVEE	approved	$0.0MQ4 2025	0	—
SUBOXONE	approved	—	4	approved

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (42)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT02511886	phase2	completed	2015-09-01	2016-01-01	Indivior Inc.	A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder
NCT03058237	phase1	completed	2017-01-24	2017-07-05	Indivior Inc.	A Phase 1 Bioavailability Study of Arbaclofen Placarbil Modified Release Formulations in Healthy Volunteers
NCT00605033	phase4	completed	2008-03-01	2009-04-01	Indivior Inc.	A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED)
NCT01846481	phase2	completed	2013-04-01	2013-06-01	Indivior Inc.	A Randomized, 4-sequence, 2-period, Double-blind, Placebo Controlled Study With a DSM-IV-TR Diagnosis of Cocaine Abuse
NCT00838396	phase2	completed	2005-10-01	2006-08-01	Indivior Inc.	A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux Disease

FDA applications (7)

Application

Approved

Type

Applicant

Products

NDA 217470

2023-05-22

NDA

INDIVIOR INC

NDA 210655

2018-07-27

NDA

INDIVIOR INC

NDA 209819

2017-11-30

NDA

INDIVIOR INC

NDA 022410

2010-08-30

NDA

INDIVIOR INC

NDA 020732

2002-10-08

NDA

INDIVIOR INC